New study tests Twice-Daily radiation to boost T-Cell attack on lymphoma

NCT ID NCT06898905

Recruiting now Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new way to give radiation before T-cell therapies (CAR T or bispecific antibodies) for people with relapsed or refractory diffuse large B-cell lymphoma. Each participant's tumor is split in half: one side gets once-daily radiation, the other gets twice-daily radiation. The goal is to see if twice-daily dosing is safer and more practical. Only 10 adults with large tumors (5 cm or bigger) will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: radiation therapy
What this could lead to: If successful, this could identify a better radiation schedule to help T-cell therapies work more effectively against large lymphoma tumors.
What could go wrong: This is a very small early feasibility study with only 10 participants, so results may not apply broadly. The main goal is safety and practicality, not yet proving which schedule is better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B-CELL LYMPHOMA

Contacts and locations

Locations

Yale University
RECRUITING

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.